Thank you for visiting DaVinci Biosciences. Please explore this section for the latest news about DaVinci Biosciences, our ground-breaking research and our therapeutics. For more information on DaVinci Biosciences please contact us.

DaVinci Biosciences and Regenerative Worldwide Announced Agreement to Utilize ReStem

Yorba Linda, CA, January 4, 2016 – Regeneration Worldwide Company, Inc., a Panamanian corporation focused on regenerative medicine, announced today their Agreement with DaVinci Biosciences, LLC, a company committed to improving the quality of life for those suffering from degenerative diseases, to utilize the Restem trademark within the United States. With this collaboration, DaVinci Biosciences will be able to provide Restem products to their clientele for therapeutic and regenerative therapy research.

 

About DaVinci Biosciences
DaVinci Biosciences is a private biotechnology company dedicated to generating technological breakthroughs in the stem cell field and to improving the quality of life for those suffering from injuries or degenerative disease. Through responsible research in conjunction with universities, medical research institutions and hospitals worldwide, DaVinci Biosciences is focused on being a leader in regenerative medicine and biotechnology, developing advancements for unmet medical needs. DaVinci Biosciences’ studies have been recognized in many publications and document results obtained in the quest to improve quality of life for those suffering from disease and injury. This alliance of hope between two countries and two professional companies, seek to provide hope to patients and relatives of those suffering from degenerative disease and injury.

Dr. Rafael Gonzalez will be presenting at the American Academy of Anti-Aging Medicine

Dr. Rafael Gonzalez will be presenting at the American Academy of Anti-Aging Medicine on September 22-24, 2016, at the Hyatt Regency in Dallas, Texas. He will be part of the Stem Cell Fellowship, Module III: Clinical Applications of Regenerative Therapies-Focus on Cardiovascular, Vascular, and Respiratory Conditions. Dr. Gonzalez will be presenting 3 different topics entitled, “Use of Cardiac Stem Cells and Cardiospheres in the Treatment of Heart Disease”, “Effects of Extracellular Vesicles in Respiratory Disease” and “Preclinical Studies in the Cellular Treatment of Lung Disease”. Come join us in this informative session on stem cells and regenerative medicine!

DaVinci Biosciences will be in Murcia, Spain July 11 – 15

DaVinci Biosciences will be in Murcia, Spain for the 33rd Annual Actividades y Cursos de Verano for the Cell Therapy: From the Bench to the Bedside and Return
sessions.

The aim of this course is the diffusion of knowledge about stem cells and their therapeutic possibilities, with a special emphasis on Hematopoietic Stem Cell Transplants and Regenerative Medicine.

The course is intended to provide a forum for scientific discussion with basic researchers and clinical experts in cell therapy, and to set out the achievements and challenges in this exciting new area of Medicine.

 
 

DaVinci Biosciences Attends A4M Conference in Fort Lauderdale

May 19, 2016 – DaVinci Biosciences attended the bi-annual A4M Conference in Fort Lauderdale, Florida May 19 – 21, 2016.

Rafael Gonzalez, PhD, the head of Research and Development Department at DaVinci Biosciences & DV Biologics, The Biobox, and Rehealth staff member, was invited to present at the American Academy of Anti-Aging Medicine Conference. Dr. Gonzalez spoke upon 4 topics: Importance of Cell Product Standardization, Cell Validation Methods and Interpretation, Autologous Adult Cell Cryopreservation & Banking Techniques and Introduction to Cell Culturing and Expansion. With over 12 years of experience, Dr. Gonzalez has become a key opinion leader in the biomedical industry and has expansive knowledge on the behavior and expansion of stem cells and stem cell cryopreservation. His research includes stem cell applications for multiple diseases, degenerative disorders and research on the behavior of stem cell cultures and cell biology from several development stages.

Cryopreservation & Culture Expansion of Stem Cells
Mesenchymal stem cells (MSCs) may be isolated from tissues such as adipose, bone marrow, umbilical cord tissue and blood. Following tissue processing, you will have the option of using your mixed cell product, such as stromal vascular fraction or purification of MSCs by expansion in culture. In 2006, there was a set of guidelines defining MSCs. One of the main characteristics is the ability to adhere to plastic. For cells to adhere to plastic, they require culture expanding MSCs and eventual cryopreservation. We will discuss methods of culture expansion and cryopreservation of MSCs. We will overview the use of the reagents necessary to start and expand MSCs. In addition, we will analyze methods of mesenchymal stem cell culture expansion and their implications in patient treatment. We will also discuss the importance and logistics of the cryopreservation process for your expanded MSCs.

Southern California Cellular Research Company Announces Publication of “Mesenchymal Stem Cells for the Treatment of Arthritis”

SOUTHERN CALIFORNIA CELLULAR RESEARCH COMPANY ANNOUNCES PUBLICATION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF ARTHRITIS” IN THE BOOK Anti-Aging Therapeutics Volume 17.

YORBA LINDA, CA. 16 August, 2015 – DaVinci Biosciences, LLC, a company committed to improving the quality of life for those suffering from degenerative diseases, announced today that the Vice President of Research and Development, Rafael Gonzalez’s, paper “Mesenchymal Stem Cells for the Treatment of Arthritis” has been published in the book Anti-Aging Therapeutics, Volume 17 on pages 87-92 (Chapter 8).

Arthritis affects 37 million U.S. citizens, and it is estimated that this figure will rise to 67 million citizens by 2030. At present, there is no cure. However, there is an abundance of research suggesting that mesenchymal stem cells may provide us with a treatment for this disease. Indeed, clinical studies have shown that mesenchymal stem cells are both safe and effective at repairing cartilage and improving both pain and function. They are the stem cells of choice because they are multipotent, they have immunomodulatory and anti-inflammatory properties and provide trophic support. This entry offers a brief introduction into the use of mesenchymal cells to treat arthritis.

“I am honored to have been published in this book and to share my findings,” stated Dr. Rafael Gonzalez. Dr. Gonzalez hopes this scientific entry will spark more interest in the use of mesenchymal stem cell for the treatment of arthritis.

About DaVinci Biosciences LLC

DaVinci Biosciences, LLC is a cellular biology based company dedicated to improving the quality of life for individuals suffering from degenerative diseases and injuries. Through responsible research and development, DaVinci strives to be innovative leaders in biotechnology and regenerative medicine; renowned worldwide for their scientific and medical achievements and contributions to the health and well-being of communities. DaVinci Biosciences is also the parent company to DV Biologics, LLC., which is a leading global supplier of human primary cells and cell-derived products. DV Biologics manufactures the highest quality biological tools for use in academic institutions and pharmaceutical laboratories engaging in cell and drug based discovery and development. DV Biologics offers normal, human-derived primary cells and cell lines for research, genomic and proteomic biological tools, and a line of disease-specific primary cells and cell lines for the most accurate study of a particular disease profile. All of DV Biologics’ products are validated under the strictest quality assurance and control parameters, providing customers with reliable, guaranteed quality products for reproducible results.

DaVinci Biosciences and DV Biologics are headquartered in Yorba Linda, California.

 

DaVinci will be in Murcia, Spain for “Cell Therapy from the Bench to the Bedside and Return”

July 12, 2105 – DaVinci Biosciences is heading overseas, yet again! We will be in Murcia, Spain, July 13-17 at the Universidad Internacional del Mar. Dr. Robert Sackstein and DaVinci Biosciences are hosting seminars throughout the week in regards to the latest trends and developments in the cell therapy and the advantages of therapy for various diseases and disorders.

We have published a paper on “Stem Cells Targeting Inflammation as Potential Anti-aging Strategies and Therapies”

FACEBOOK_LibertasAmericaJuly 3, 2015 – DaVinci Biosciences, LLC, a company committed to improving the quality of life for those suffering from degenerative diseases, announced today that their paper on “Stem Cells Targeting Inflammation as Potential Anti-Aging Strategies and Therapies” has been accepted for publication in the peer-reviewed journal Cell & Tissue Transplantation & Therapy.

For many years medicine has focused on prolonging lifespans and reversing the aging process. Today, anti-aging has become a major focus among the community, physicians and scientists throughout the world. As the scientific community continues researching methods to reverse aging, Dr. Rafael Gonzalez, Vice President of Research and Development of DaVinci Biosciences, , Dr. Dave Woynarowski, a leading anti-aging doctor and author of the book, “The Immortality Edge” and Dr. Luis Geffner, a pioneer in the stem cell field, believe that stem cells may serve as an anti-aging strategy.

Stem cells, particularly mesenchymal stem cells, have properties that may help control inflammation. Inflammation has proven to be a key mediator in diseases of aging such as heart disease, physical disability and cognitive decline. Through research, the authors have identified that there are 3 key mediators of inflammation that can be monitored and may predict morbidity and mortality. Stem cells may help control these 3 mediators and deter the degeneration caused by the inflammatory response during aging. “We are happy to be the first to publish on the process of using stem cells as anti-aging strategies. The unique properties of stem cells could potentially benefit the aging population Inflammation plays a key role in disease and stem cells control the inflammatory process, therefore it makes sense to use stem cells to slow down that detrimental effect,” stated Dr. Rafael Gonzalez.. DaVinci Biosciences hopes this scientific publication will spark more interest in the use of stem cells for anti-aging strategies.

DaVinci Biosciences and DV Biologics are moving!

June 24, 2015 – We are pleased to announce that DaVinci Biosciences, LLC and DV Biologics, LLC will be relocating their laboratory to Yorba Linda, DaVinci_Office_SmallCalifornia, effective June 24, 2015.

The new laboratory will now be located at 22667 Old Canal Road, Yorba Linda, CA 92887 in the North County Business Center. This new location boasts +7,000 square feet. This space will allow for a new state-of-the-art cell culture room, a larger quality control and regulatory affairs area and a larger cryopreservation storage area for The BioBox, LLC. The new cell culture facility will house two separate areas, which will be ISO 7 clean rooms. This will enable DaVinci Biosciences and DV Biologics to continue producing cells under current good manufacturing practices (cGMP) for future research and clinical studies with the lead product ReStem.

Dr. Rafael Gonzalez, DaVinci Biosciences’ Vice President of Research and Development states, “We are excited to be in our new facility. It will house 2 new cell culture areas that are ISO 7 clean rooms. This will help DaVinci Biosciences and its affiliates grow tremendously and allow us the opportunity to produce the best quality cells in the world. With our continual research, we look forward to our cells being in clinical trials relatively soon.”

The extra space will also support the contiguous growth of both DaVinci Biosciences and DV Biologics.

DaVinci Biosciences to Speak at RIO Grupo Stem Cell Conference

a4aJanuary 23, 2015DaVinci Biosciences Vicepresident of Research and Development, Rafael Gonzalez, Ph.D, has been invited to speak at the 17th annual “Curso Internacional de Actualización Clínico Radiológico” on January 23, 2015 at 1:15 p.m. located at the RIU Plaza Guadalajara Hotel in Mexico. Dr. Gonzalez will be lecturing on the advantages and breakthroughs in stem cell therapy.
The conference is organized by the RIO Grupo, whose mission is to bring together renowned local, national and international speakers in order to provide continuous training for their State Medical Guild. At this seminar, participants will learn about new diagnostic technologies, imagining study protocols for orthopedics and neurology and establish new networking relationships.
For more information on the conference and RIO Grupo, please visit.
Read more

DaVinci goes to A4M in Las Vegas

a4aDecember 10, 2014 – Join us on December 11-13, 2014 at The Venetian in Las Vegas for the bi-annual A4M Conference. We kindly invite you to visit us at booths 5022 and 5020 to learn how regenerative medicine is the future of medicine and how it aims to treat diseases and degenerative disorders.

Rafael Gonzalez, PhD, the head of Research and Development Department at DaVinci Biosciences & DV Biologics, The Biobox, and Rehealth staff member, was invited to present at the American Academy of Anti-Aging Medicine Conference in Las Vegas on December 11, 2014 at 1:40 pm. With over 12 years of experience, Dr. Gonzalez has become a key opinion leader in the biomedical industry and has expansive knowledge on the behavior and expansion of stem cells and stem cell cryopreservation. His research includes stem cell applications for multiple diseases, degenerative disorders and research on the behavior of stem cell cultures and cell biology from several development stages.
Cryopreservation & Culture Expansion of Stem Cells
Mesenchymal stem cells (MSCs) may be isolated from tissues such as adipose, bone marrow, umbilical cord tissue and blood. Following tissue processing, you will have the option of using your mixed cell product, such as stromal vascular fraction or purification of MSCs by expansion in culture. In 2006, there was a set of guidelines defining MSCs. One of the main characteristics is the ability to adhere to plastic. For cells to adhere to plastic, they require culture expanding MSCs and eventual cryopreservation. We will discuss methods of culture expansion and cryopreservation of MSCs. We will overview the use of the reagents necessary to start and expand MSCs. In addition, we will analyze methods of mesenchymal stem cell culture expansion and their implications in patient treatment. We will also discuss the importance and logistics of the cryopreservation process for your expanded MSCs.

DaVinci attends the 3rd International Conference & Exhibition on Cell & Gene Therapy

CellThearpy-2014_BannerOctober 27-29, 2014 – DaVinci Biosciences will be attending the 3rd International Conference and Exhibition on Cell & Gene Therapy to be held during October 27-29, 2014 at Las Vegas, USA. Cell Therapy-2014 is a remarkable event which brings together a unique and International mix of leading oncologists, academic scientists, industry researchers and scholars to exchange and share their experiences and research results about all aspects, making the Congress a perfect platform to share experience and which paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in emerging cell & gene therapies.The scientific program will include workshops, symposia and poster sessions on a wide collection of Cell & Gene Therapy topics. Dr Rafael Gonzalez, Vice President of Research & Development for DaVinci Biosciences will discuss the use of bone marrow stem cells in osteoarthritis. For more information on this event visit:
Read more

DaVinci Biosciences To Give Lecture on Stem Cell Research

1410410846October 17-19, 2014 – DaVinci Biosciences will be attending the 2nd Annual “Topicos en Especialidades Medicas y Actualizaciones”, on Friday, October 17 through Sunday, October 19 located at the Westin Hotel in Puerto Vallarta, Mexico.

The “Topicos en Especialidades Medicas y Actualizaciones” conference will be a dissemination of scientific knowledge in order to provide patients with optimal care and updating professionals on current topics and controversial issues in the field of medicine. There will also be a high level of participation of various renowned physicians from different disciplines participating at the event on October 17.

DaVinci Biosciences Will Present at World Stem Cell Conference

a4aSeptember 9, 2014 – Rehealth will be attending the 2014 World Stem Cells and Regenerative Medicine congress at the Westin Copley Place, Boston MA.
Dr Rafael Gonzalez, VP of Research & Development of DaVinci Biosciences, DVBiologics, The Biobox, and Rehealth staff member, was invited to speak at the Pitch & Partner session on Monday, September 15th session. He will discuss using DaVinci Biosciences patented technology in a talk entitled, “Using umbilical cord lining stem cells as an off-the shelf product for osteoarthritis”. In addition, he will chair the stem cell morning session on Tuesday, September 16th.,

For any question, please feel free to come visit us in Boston or find out more about Dr. Gonzalez’s lecture at For any question, please feel free to come visit us in Boston or find out more about Dr. Gonzalez’s lecture at http://www.terrapinn.com/conference/stem-cells-and-regenerative-medicine-congress/speaker-rafael-GONZALEZ.stm

DaVinci Biosciences and The BioBox Unite to Create a Revolutionary Adult Stem Cell Bank

July 29, 2014DaVinci Biosciences, a leader in the cell and stem cell biology biotechnology research industry, and The BioBox, a revolutionary adult stem cell cryopreservation bank, have begun collaborating in efforts of establishing the best technologically advanced cryobank.
DaVinci Biosciences is dedicated to improving the quality of life of patients suffering from various diseases using stem cellsgenerating technological breakthroughs in the stem cell field. The team of renowned scientists at DaVinci Biosciences has done extensive research and is well has been published in numerous scientific journals. DaVinci Biosciences has spent years perfecting isolation and throughout the years on perfecting the isolation and cryopreservation of human cells and adult stem cells.
he BioBox is an innovative adult stem cell bank focused on providing hope for today’s advancements and tomorrow’s health solutions. The company is dedicated to upholding the finest standards and providing the safest, most secure storage for your stem cells.

Both The BioBox and DaVinci Biosciences have invested long hours and millions of dollars into the research of isolating cells from numerous tissues and the best methods of cryopreservation. Through responsible research and use of the best technologies, in conjunction with The BioBox, DaVinci Biosciences has been able to achieve the most efficient and best practices for cryopreserving cells. The BioBox, an FDA registered company can now begin cryopreserving your fat and bone marrow stem cells.

DaVinci Biosciences Publishes Paper in Renowned Scientific Journal

May 19, 2014DaVinci Biosciences, LLC and its sister company DVBiologics announced today that their paper “Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells; Phenotypic and Functional Characterization” has been accepted for publication in the peer-reviewed journal CELL & TISSUE TRANSPLANTATION & THERAPY.
With the current move by researchers and governments to reduce the use of animals in drug development and testing, scientist are looking for better and more cost effective ways to conduct their research for new and novel drugs for human disease. DVBiologics recognizes the need for new methods and models that will help get compounds from the bench top to clinical trials and has been continuously working to isolate and develop human primary cells for this purpose.
DaVinci Biosciences continues to research and develop cellular biology models that will promote the use of responsible science for the development and implementation of new approaches in the discovery of new regenerative medicine therapies. “It is a pleasure to work with DV Biologics in developing new cell based models for research and drug development. Our goal is to find more realistic models that may mimic the in vivo system,” says Dr. Rafael Gonzalez, VP of Research and Development of DVBiologics. “It is our belief that these cell models will enable researchers to reduce the amount of animals used in drug discovery while getting faster results in the compounds safety and efficacy,” says Tony Delamaza, Vice President of Sales of DaVinci Biosciences, regarding the use of human primary cells.
About DaVinci Biosciences
DaVinci Biosciences is a leading global research and development company of human primary cells, cell derived products, and processes. DaVinci Biosciences distributes its cells and licenses its patents through its sister company DV Biologics.
About DV Biologics LLC
DV Biologics is a leading global supplier of human primary cells and cell-derived products. DV Biologics manufactures the highest quality biological tools for use in academic institutions and pharmaceutical laboratories engaging in cell and drug based discovery and development. DV Biologics offers normal, human-derived primary cells and cell lines for research, genomic and proteomic biological tools, and a line of disease-specific primary cells and cell lines for the most accurate study of a particular disease profile. All of DV Biologics’ products are validated under the strictest quality assurance and control parameters, providing customers with reliable, guaranteed quality products for reproducible results

DaVinci Biosciences Delivers Lecture on Arthritis at A4M Conference

a4aJune 2, 2014 – Rafael Gonzalez, PhD, the head of Research and Development Department at DaVinci Biosciences, was invited to present at the American Academy of Anti-Aging Medicine Conference in Orlando on May 17, 2014. With over 12 years of experience, Dr. Gonzalez has become a key opinion leader in the biomedical industry and has expansive knowledge on the behavior of stem cells and stem cell-based regenerative medicine in arthritis. His research includes clinical stem cell applications for multiple diseases, degenerative disorders and research on the behavior of stem cell cultures and cell biology from several development stages.
The American Academy of Anti-Aging Medicine, also known as A4M, is a well respected non-profit organization that is dedicated to the advancement of technology in detecting, preventing and treating aging related diseases and promoting research in the aging process. A4M holds one of the largest conferences bi-annually on anti-aging, and regenerative and aesthetic medicine. This year, Dr. Gonzalez was afforded the opportunity to present as a key note speaker on the use of mesenchymal stem cells in the treatment of arthritis. Below is an abstract of his presentation.
Mesenchymal Stem Cells for the Treatment of Arthritis: Translation From Clinical Research to Standard of Care in Clinical Practice
According to the World Health Organization (WHO), musculoskeletal disease is the most common cause of severe long-term pain and disability. The Centers for Disease Control (CDC), reports one in five adults in the United States having doctor-diagnosed arthritis. By 2030, an estimated 67 million Americans ages 18 years or older are projected to have doctor-diagnosed arthritis. Current treatments for these conditions are limited in that they merely treat the symptoms of the condition, rather than addressing prevention or cure. Additionally, many systemic remedies have undesirable gastrointestinal, renal, hepatic, and cardiac side effects.
Both osteoarthritis and rheumatoid arthritis both possess inflammatory and immunological involvement, which makes treatment confounding. Mesenchymal stem cells are non-hematopoietic progenitor cells isolated from adult tissues that possess immunosuppression and anti-inflammatory effects. Mesenchymal stem cells possess the ability to differentiate into osteoblasts (bone), adipocytes (fat), and chrondrocytes (cartilage). Additionally, they aid in tissue regeneration in two ways. First, mesenchymal cells secrete growth factors (transforming growth factor-beta, insulin-like growth factors, fibroblast growth factors, platelet-derived growth factors, and Wnts), which exert trophic effects on surrounding cells. Second, they have the ability to coordinate tandem differentiation with differentiated and undifferentiated host cells. These combined characteristics make mesenchymal stem cells an attractive therapeutic option for the treatment of arthritis.
The purpose of this presentation is to translate the research literature, protocols, and procedures into reproducible results that can be used in-office to effectively treat arthritic conditions. A comprehensive review of the literature and research to date on the use of autologous adipose-derived and bone marrow-derived mesenchymal stem cells at the point of care utilizing the stromal vascular fraction for the treatment of arthritis will be provided. The use of autologous mesenchymal culture expanded cells (bone marrow and adipose derived) in the treatment of osteoarthritis will be reviewed, as well as the use of allogeneic mesenchymal cells in osteoarthritis and rheumatoid arthritis treatments. Finally, the prospect of cryopreservation, cell banking, and culture expansion of mesenchymal stem cells will be discussed.

DaVinci Biosciences to exhibit at A4M Annual Meeting in Orlando

DaVinci BiosciencesApril 22, 2014 – DaVinci Biosciences will be at the American Academy for Anti-aging Medicine come May 15-17th. Dr Rafael Gonzalez, Vice President of Research & Development for DaVinci Biosciences, will be presenting on several topics. Dr. Gonzalez will be presenting two specialty workshops on Thursday, May 15th: “The Importance of Standardizing and Characterizing you Stem Cell Product” and “Cryopreservation and Culture Expansion of Stem Cells” as part of the Stem Cell in Anti-aging: An Update workshop. On Saturday, May 17th, he will be presenting in the general session, “Mesenchymal Stem Cells for the Treatment of Arthritis”.

DaVinci will be attending the 3rd International Conference and Exhibition on Cell & Gene Therapy

CellThearpy-2014_BannerOctober 27-29, 2014 – DaVinci Biosciences will be attending the 3rd International Conference and Exhibition on Cell & Gene Therapy to be held during October 27-29, 2014 at Las Vegas, USA. Cell Therapy-2014 is a remarkable event which brings together a unique and International mix of leading oncologists, academic scientists, industry researchers and scholars to exchange and share their experiences and research results about all aspects, making the Congress a perfect platform to share experience and which paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in emerging cell & gene therapies.The scientific program will include workshops, symposia and poster sessions on a wide collection of Cell & Gene Therapy topics. Dr Rafael Gonzalez, Vice President of Research & Development for DaVinci Biosciences will discuss the use of bone marrow stem cells in osteoarthritis. For more information on this event visit:
Read more

DaVinci Biosciences & Cellteam Biotechnology Combine Their Knowledge in the Stem Cell Field

April 2, 2012 – Cellteam Biotechnology, a company based in Guadalajara, Mexico and DaVinci Biosciences LLC, a biotechnology laboratory based in Costa Mesa, California, USA, today announced their Cooperation Agreement to combine the expertise and technology that will be shared between the companies in the field of clinical application of stem cell therapies.
 The two-year agreement will allow Cellteam Biotechnology to combine their technology with the Good Laboratory Practices (GLP) and technical knowledge developed in DaVinci Biosciences’ research laboratory; where research-grade biological tools are developed to progress future therapeutic applications. DaVinci Biosciences has several publications that support the seriousness of its research, and the feasibility of clinical applications using stem cells and cell-based tools. Additionally, Cellteam Biotechnology has COFEPRIS approved protocols for autologous stem cell application (cells used by a patient after being obtained from the patient’s own bone marrow) and will provide clinical feedback to DaVinci Biosciences during treatments.
About Cellteam Biotechnology
The medical team that comprises Cellteam Biotechnology has over seven years experience in the treatment of heart disease, cardiovascular disease, heart failure, ischemic heart disease, stroke, vasculitis and limb ischemia with vascular problems. Also, treatments using platelet rich plasma (PRP) for trauma have been successful. By cooperating with DaVinci Biosciences, Cellteam Biotechnology is looking to expand their knowledge in the stem cell field, in order to develop treatment protocols for investigative therapies for sports injury, diabetes, smoking-related pulmonary damage, chronic obstructive pulmonary disease, neurological diseases, spinal cord injury, immunological disease, arthritis, osteoarthritis, and ulcers. These, along with other diseases, are giving way to the body’s natural power to mitigate degeneration.
About DaVinci Biosciences
DaVinci Biosciences is a private biotechnology company dedicated to generating technological breakthroughs in the stem cell field and to improving the quality of life for those suffering from injuries or degenerative disease. Through responsible research in conjunction with universities, medical research institutions and hospitals worldwide, DaVinci Biosciences is focused on being a leader in regenerative medicine and biotechnology, developing advancements for unmet medical needs. DaVinci Biosciences’ studies have been recognized in many publications and document results obtained in the quest to improve quality of life for those suffering from disease and injury. This alliance of hope between two countries and two professional companies, seek to provide hope to patients and relatives of those suffering from degenerative disease and injury.

Santo Domingo – Dominican Republic Autologous Stem Cells Conference

March 6, 2012 – After the success and subsequent additional interest generated as a result of DaVinci Biosciences’ participation in the November 2011 “Current and Future Use of Stem Cells in the Treatment of Neurological and Cardiac Disease and Sports Injury” presentation led in part by Dr. Rafael Gonzalez, Vice President of Research and Development for DaVinci Biosciences, USA; DaVinci Biosciences was again asked to return by special invitation to speak at the conference entitled “Advances in the Use of Stem Cells in Autoimmune and Degenerative Diseases” held in one of the most prestigious hotels in the Dominican capital. The event was hosted by BRC Center and Dr. Alejandro Dominguez Brito and is the second in a planned series of discussions to take place in Santo Domingo, aimed at educating the community on the current state and future therapeutic applications of stem cells.
Both physicians and patients attended the conference as Dr. Rafael Gonzalez was joined by leaders in the stem cell and regenerative medicine field, including Dr. Jesus Esparragoza Romano, Interventional Cardiologist and Medical Director for Cellteam Biotechnology in Guadalajara, Mexico, and Dr. Maria del Pilar Santacruz, Medical Director for CellGen Technologies in Ecuador. The conference focused on the ethical and successful application of autologous stem cell therapies which result from the use of a patient’s own stem cells for therapeutic effect and improvement of quality of life for those suffering from disease and injury. Discussions focused on the quantifiable scientific effects of such procedures and specifically on statistical data including those published in peer reviewed journals supporting the efficacy of such treatments. Video testimony shared from patients that had undergone such therapies gave hope to hundreds of audience members that this is truly a revolutionary approach to treating disease.
Dr. Dominguez Brito, a respected physician in the Dominican Republic, is responsible for evaluating patients who may be good candidates for autologous stem cell therapies. Dr. Dominguez Brito works closely with hospitals and treatment centers to make sure qualified candidates receive optimal and individualized treatment tailored to their specific need, be it for autoimmune, vascular, cardiac, pulmonary, neurological or orthopedic diseases; providing hope for individual families as well as to the field of regenerative medicine on a global level.

Discussion on Advances in Autologous Stem Cell Therapies

December 14, 2011 – DaVinci Biosciences was invited to participate in a discussion entitled “Advances in Investigational Autologous Stem Cell Therapies” held at Omni Hospital in Guayaquil, Ecuador. Dr. Rafael Gonzalez, PhD, Vice President of Research and Development for DaVinci Biosciences, USA joined Dr. Maria del Pilar Santa Cruz, Medical Director for Cellgen Technologies, Ecuador and Dr. Manuel Navarro, Endocrinologist for Cellgen Technologies, Ecuador, to discuss advances in stem cell research and clinical applications for cardiovascular, endocrine and neurodegenerative diseases.
The discussion generated great interest among leading physicians of various specialties within Ecuador. In attendance also was Dr. Gonzalo W. Maitta Mendoza, Dean of the Medical Faculty of Universidad de Guayaquil, Ecuador, Dr. Luis Sarrazin, former Minister of Public Health, Ecuador, and Biologists Alexandra Narvaez and Edith Lopez of Universidad Espiritu Santo, Ecuador, all prominent key opinion leaders in the field of stem cell therapy and research.

Santo Domingo, Dominican Republic: The Future of Stem Cells Presentation

November 2011 – A lecture entitled “Current and Future Use of Stem Cells in the Treatment of Neurological and Cardiac Disease and Sports Injury” by Dr. Rafael Gonzalez, Vice President of Research and Development for DaVinci Biosciences, USA, along with Dr. Maria del Pilar Santacruz, Medical Director for CellGen Technologies at Omni Hospital, Ecuador was given in the presence of leading regenerative medicine professionals in the Domincan Republic. The meeting was organized by DaVinci Biosciences and focused on the clinical applications of stem cells for degenerative disorders for which the company is in active development. Dr. Gonzalez is responsible for the design and implementation of DaVinci’s pre-clinical and clinical therapeutic adult stem cell development which includes stem cells isolated from bone marrow, menstrual blood, and fat. Dr. Santacruz’s efforts have helped progress the initial therapeutic treatment approvals by governmental agencies to successful autologous stem cell transplants, leading to treatment of degenerative and autoimmune diseases in Ecuador’s finest clinical facility.

An Efficient Approach to Isolation and Characterization of Pre- and Postnatal Umbilical Cord Lining Stem Cells for Clinical Applications

April 2010 – In a paper published in the scientific journal Cell Transplantation, volume 19, 1439-1449, 2010, DaVinci Biosciences describes “An Efficient Approach to Isolation and Characterization of Pre- and Postnatal Umbilical Cord Lining Stem Cells for Clinical Applications”.
Read Article

DaVinci will be speaking at XII Congreso Internacional Avances en Medicina 2010

February 24th – 27th, 2010 – DaVinci Biosciences will be speaking at XII Congreso Internacional Avances en Medicina 2010, Hospital Civil de Guadalajara
The conference will be held in Expo Guadalajara, from February 24th to 27th, 2010.

DaVinci signs technology licensing agreement with Cryobanks India

January 2010 – DaVinci Biosciences signs technology licensing agreement with Cryobanks India to enable the production of Umbilical Cord Lining Stem Cells. For more information contact us directly.

January 30, 2010

Dr Rafael Gonzalez, Director of Research & Development invited to present DaVinci Biosciences’ work on mesenchymal stem cells at the National Science Forum in Guayaquil, Ecuador. The presentation entitled, ”Isolation of Mesenchymal Stem Cells from Various Adult Sources”, covers various forms of mesenchymal stem cell characterization and studies by DaVinci Biosciences.

Cell Transplantation (Issue Vol.19 No.3)

In a paper published in the Vol.19 No.3 issue of Cell Transplantation, DaVinci Biosciences publishes a safety and feasibility trial for treating patients suffering from acute and chronic spinal cord injury using stem cells.
Read the abstract for “Administration of Autologous Bone Marrow Stem Cells Into Spinal Cord Injury Patients Via Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive Case Studies” published in Cell Transplantation.

SFN 2009 Presentation

Administration of Adult Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes is Safe and Feasible.
View Newsletter

October 21, 2009

DaVinci Biosciences’ presentation at Society for Neuroscience Annual Meeting earns label of “Hot Topic”.

October 19, 2009

Presentation of adult stem cell study highlights promising application of autologous stem cells for treatment of spinal cord injury.
Read Press Release

June 8, 2009

Orthopedics This Week highlights article published by DaVinci Biosciences.
Read Article

June 4, 2009

In a paper published in the scientific journal of Biochemical and Biophysical Research Communications, volume 385, 2009 DaVinci Biosciences describes a novel source of stem cells easily isolated from adult human testes.
Read Article

June 4, 2009

International stem cell collaboration results in discovery of promising new stem cell type.
Read Press Release

March 12, 2009

Stem cell administration study demonstrates improved quality of life for patients suffering from spinal cord injury.
Read Press Release

Davinci exhibits at the 3rd International Conference and Exhibition on Cell & Gene Therapy

CellThearpy-2014_BannerOctober 27-29, 2014 – DaVinci Biosciences will be attending the 3rd International Conference and Exhibition on Cell & Gene Therapy to be held during October 27-29, 2014 at Las Vegas, USA. Cell Therapy-2014 is a remarkable event which brings together a unique and International mix of leading oncologists, academic scientists, industry researchers and scholars to exchange and share their experiences and research results about all aspects, making the Congress a perfect platform to share experience and which paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in emerging cell & gene therapies.The scientific program will include workshops, symposia and poster sessions on a wide collection of Cell & Gene Therapy topics. Dr Rafael Gonzalez, Vice President of Research & Development for DaVinci Biosciences will discuss the use of bone marrow stem cells in osteoarthritis. For more information on this event visit:
> Read more